Mammary Cell News Volume 3.45 | Nov 17 2011

The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells
Scientists show that the activity of TAZ, a transducer of the Hippo pathway, is required to sustain self-renewal and tumor-initiation capacities in breast cancer stem cells. [Cell] Abstract

Recognition of Enhancer Element–Specific Histone Methylation by TIP60 in Transcriptional Activation
Researchers demonstrate that multiple protein-protein interactions by the protein acetyltransferase TIP60 are required for estrogen-induced transcription of a subset of estrogen receptor alpha target genes in human cells. [Nat Struct Mol Biol] Abstract | Press Release

Interplay Between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer
Here investigators depict a molecular mechanism involving BRCA1 and RHAMM that regulates apicobasal polarity and, when perturbed, may increase risk of breast cancer. [PLoS Biol] Abstract | Press Release

Global Characterization of the SRC-1 Transcriptome Identifies ADAM22 as an ER-Independent Mediator of Endocrine Resistant Breast Cancer
Findings suggest that SRC-1 switches steroid-responsive tumors to a steroid resistant state in which the SRC-1 target gene ADAM22 has a critical role, suggesting this molecule as a prognostic and therapeutic drug target that could help improve the treatment of endocrine-resistant breast cancer. [Cancer Res] Abstract

Gene Expression Profile in Response to Doxorubicin-Rapamycin Combined Treatment of HER-2 Overexpressing Human Mammary Epithelial Cell Lines
Here scientists investigated whether rapamycin increased the sensitivity to doxorubicin therapy in two HER-2 over-expressing cell lines: C5.2, which was derived from the parental HB4a by transfection with HER-2 and SKBR3, which exhibits HER-2 amplification. [Mol Cancer Ther] Abstract

A Monoclonal Antibody Against Human Notch1 Ligand Binding Domain Depletes Subpopulation of Breast Cancer Stem-Like Cells
Researchers report characterization of Notch1 monoclonal antibodies with therapeutic potential. [Mol Cancer Ther] Abstract

Significance of PELP1 in ER-Negative Breast Cancer Metastasis
Investigators examined the mechanism and significance of PELP1-mediated signaling in estrogen receptor (ER)-negative breast cancer progression using two ER-negative model cells (MDA-MB231 and 4T1 cells) that stably express PELP1-shRNA. [Mol Cancer Res] Abstract

CLINICAL RESEARCH

Gemcitabine Plus Docetaxel Versus Docetaxel in Patients with Predominantly Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer: A Randomized, Phase III Study by the Danish Breast Cancer Cooperative Group
The objective of this phase III study was to compare the efficacy of gemcitabine plus docetaxel versus docetaxel in patients with advanced breast cancer. [J Clin Oncol] Abstract

Young Women with Family History of Breast Cancer and Their Risk Factors for Benign Breast Disease
The authors investigated childhood/adolescent risk factors for benign breast disease among girls with a family history. [Cancer] Abstract | Press Release

Signaling Pathway Linked to Inflammatory Breast Cancer May Drive Disease Metastasis
Amplification of anaplastic lymphoma kinase may be a primary driver of the rapid metastasis that patients with inflammatory breast cancer experience. [Press release from EurekAlert! discussing research presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco]
Press Release

Research Gives Hope to Women with Deadliest Breast Cancer
In a recent study, scientists pinpointed a key driver in inflammatory breast cancer that is leading to new ways to treat it. [Press release from EurekAlert! discussing research presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco] Press Release

Syndax Pharmaceuticals Presents Data Linking Pharmacodynamic Marker to Clinical Benefit in Advanced Breast Cancer Patients
Syndax Pharmaceuticals, Inc. announced that pharmacodynamic analysis in a subset of patients from ENCORE 301 demonstrates the association of the pharmacodynamic marker lysine hyperacetylation with clinical outcome. [Press release from Syndax Pharmaceuticals, Inc. discussing research presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco] Press Release

Advaxis Licenses Novel Antigen for Severe Breast Cancer and Other Tumor Types
Advaxis, Inc. has exclusively licensed the use of antigen ISG15 in Advaxis’ Lm-LLO based immunotherapies from the University of Pennsylvania. This intellectual property resulted from research conducted in Dr. Yvonne Paterson’s laboratory that demonstrated ISG15 was an effective immunological target for the treatment of breast cancer in animal models. [Advaxis, Inc.] Press Release

Visit our events page to see a complete list of events in the mammary cell community.

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientific Marketing Communications Specialist (STEMCELL Technologies, Inc.)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Postdoctoral Training Fellow, Molecular Pathology Team (The Institute of Cancer Research)

Postdoctoral Fellow in Breast Cancer (Indiana University School of Medicine)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.